Papers
18
Total Citations
493
H-Index
14
About
Dennie Meijer is a prominent urological oncology researcher whose work has fundamentally advanced the use of prostate-specific membrane antigen (PSMA) positron emission tomography imaging in prostate cancer diagnosis, staging, and treatment planning. With a body of work accumulating over 400 citations, Meijer has established himself as a leading voice in translating cutting-edge molecular imaging into clinical practice. His most influential contribution, the SALT trial (2020, 106 citations), demonstrated the superior capability of ¹⁸F-DCFPyL PET/CT over conventional imaging for detecting pelvic lymph-node metastases in primary prostate cancer — a finding with direct implications for surgical planning and patient selection for extended pelvic lymph-node dissection. Complementing this, his development and validation of novel nomograms incorporating PSMA PET/CT has significantly refined preoperative risk stratification tools used internationally. Meijer has further explored PSMA PET's role in guiding targeted biopsies, predicting oncological outcomes through standardized uptake values, and optimizing salvage radiation therapy decisions in biochemically recurrent disease. His prospective studies comparing PSMA PET/MRI with multiparametric MRI have helped define next-generation diagnostic workflows. Collectively, his research positions PSMA-based imaging not merely as a diagnostic adjunct but as a transformative tool reshaping prostate cancer management from detection through treatment response.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10